Found: 76
Select item for more details and to access through your institution.
Noise sensitivity of <sup>89</sup>Zr-Immuno-PET radiomics based on count-reduced clinical images.
- Published in:
- EJNMMI Physics, 2022, v. 9, n. 1, p. 1, doi. 10.1186/s40658-022-00444-4
- By:
- Publication type:
- Article
Cerebral rituximab uptake in multiple sclerosis: A <sup>89</sup>Zr-immunoPET pilot study.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 4, p. 543, doi. 10.1177/1352458517704507
- By:
- Publication type:
- Article
The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 4, p. N.PAG, doi. 10.3390/ph15040450
- By:
- Publication type:
- Article
Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice.
- Published in:
- Head & Neck, 1989, v. 11, n. 6, p. 511, doi. 10.1002/hed.2880110607
- By:
- Publication type:
- Article
Improving Routine <sup>89</sup>Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐N‐suc‐TFP Ester Over p‐NCS‐Bz‐DFO.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2024, v. 67, n. 8, p. 280, doi. 10.1002/jlcr.4097
- By:
- Publication type:
- Article
Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe.
- Published in:
- EJNMMI Research, 2018, v. 8, n. 1, p. 0, doi. 10.1186/s13550-018-0368-6
- By:
- Publication type:
- Article
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.
- Published in:
- EJNMMI Research, 2018, v. 8, n. 1, p. 1, doi. 10.1186/s13550-018-0358-8
- By:
- Publication type:
- Article
Platinum(II) as Bifunctional Linker in Antibody-Drug Conjugate Formation: Coupling of a 4-Nitrobenzo-2-oxa-1,3-diazole Fluorophore to Trastuzumab as a Model.
- Published in:
- ChemMedChem, 2015, v. 10, n. 5, p. 797, doi. 10.1002/cmdc.201402496
- By:
- Publication type:
- Article
Validation of simplified uptake measures against dynamic Patlak K<sub>i</sub> for quantification of lesional <sup>89</sup>Zr-Immuno-PET antibody uptake.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 7, p. 1897, doi. 10.1007/s00259-023-06151-1
- By:
- Publication type:
- Article
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 3, p. 694, doi. 10.1007/s00259-020-05002-7
- By:
- Publication type:
- Article
Interobserver reproducibility of tumor uptake quantification with <sup>89</sup>Zr-immuno-PET: a multicenter analysis.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2019, v. 46, n. 9, p. 1840, doi. 10.1007/s00259-019-04377-6
- By:
- Publication type:
- Article
Advancing <sup>89</sup>Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody -- The choice of chelator is essential.
- Published in:
- Theranostics, 2022, v. 12, n. 16, p. 7067, doi. 10.7150/thno.73509
- By:
- Publication type:
- Article
Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101).
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0082331
- By:
- Publication type:
- Article
Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience.
- Published in:
- Head & Neck, 2001, v. 23, n. 7, p. 559, doi. 10.1002/hed.1078
- By:
- Publication type:
- Article
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2010, v. 37, n. 2, p. 250, doi. 10.1007/s00259-009-1263-1
- By:
- Publication type:
- Article
<sup>124</sup>I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of <sup>131</sup>I-L19-SIP radioimmunotherapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2009, v. 36, n. 8, p. 1235, doi. 10.1007/s00259-009-1096-y
- By:
- Publication type:
- Article
Quantitative PET imaging of Met-expressing human cancer xenografts with <sup>89</sup>Zr-labelled monoclonal antibody DN30.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2008, v. 35, n. 10, p. 1857, doi. 10.1007/s00259-008-0774-5
- By:
- Publication type:
- Article
Preparation and evaluation of <sup>89</sup>Zr-Zevalin for monitoring of <sup>90</sup>Y-Zevalin biodistribution with positron emission tomography.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2006, v. 33, n. 11, p. 1337, doi. 10.1007/s00259-006-0160-0
- By:
- Publication type:
- Article
High-quality<sup>124</sup>I-labelled monoclonal antibodies for use as PET scouting agents prior to<sup>131</sup>I-radioimmunotherapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2004, v. 31, n. 12, p. 1645, doi. 10.1007/s00259-004-1632-8
- By:
- Publication type:
- Article
How to obtain the image-derived blood concentration from <sup>89</sup>Zr-immuno-PET scans.
- Published in:
- EJNMMI Physics, 2024, v. 11, n. 1, p. 1, doi. 10.1186/s40658-024-00621-7
- By:
- Publication type:
- Article
Synthesis and preclinical evaluation of [<sup>11</sup>C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.
- Published in:
- EJNMMI Research, 2024, v. 14, p. 1, doi. 10.1186/s13550-024-01078-6
- By:
- Publication type:
- Article
Non-specific irreversible <sup>89</sup>Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using <sup>89</sup>Zr-immuno-PET.
- Published in:
- EJNMMI Research, 2024, v. 14, p. 1, doi. 10.1186/s13550-024-01079-5
- By:
- Publication type:
- Article
PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients.
- Published in:
- Advanced Materials, 2022, v. 34, n. 21, p. 1, doi. 10.1002/adma.202201043
- By:
- Publication type:
- Article
Safety, biodistribution, pharmacokinetics, and immunogenicity of <sup>99m</sup>Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 9, p. 576, doi. 10.1007/s00262-003-0396-5
- By:
- Publication type:
- Article
Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-infrared Fluorescent Anti--Epidermal Growth Factor Receptor Nanobody.
- Published in:
- Molecular Imaging, 2012, v. 11, n. 1, p. 33, doi. 10.2310/7290.2011.00025
- By:
- Publication type:
- Article
Good practices for <sup>89</sup>Zr radiopharmaceutical production and quality control.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00258-y
- By:
- Publication type:
- Article
Potential and pitfalls of <sup>89</sup>Zr-immuno-PET to assess target status: <sup>89</sup>Zr-trastuzumab as an example.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00813-7
- By:
- Publication type:
- Article
Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
- Published in:
- International Journal of Cancer, 1998, v. 77, n. 1, p. 13, doi. 10.1002/(SICI)1097-0215(19980703)77:1<13::AID-IJC3>3.0.CO;2-2
- By:
- Publication type:
- Article
Performance of <sup>89</sup>Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
- Published in:
- PLoS ONE, 2017, v. 12, n. 1, p. 1, doi. 10.1371/journal.pone.0169828
- By:
- Publication type:
- Article
High dose rhenium-186-labeling of monoclonal antibodies for clinical application.
- Published in:
- Cancer (0008543X), 1997, v. 80, n. S12, p. 2360, doi. 10.1002/(SICI)1097-0142(19971215)80:12+<2360::AID-CNCR5>3.0.CO;2-F
- By:
- Publication type:
- Article
A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Evaluation of Limited Blood Sampling in a Preceding <sup>99m</sup>Tc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of <sup>186</sup>Re-cMAb U36 Radioimmunotherapy.
- Published in:
- Journal of Nuclear Medicine, 2001, v. 42, n. 9, p. 1364
- By:
- Publication type:
- Article
Phase I Therapy Study of <sup>186</sup>Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck.
- Published in:
- Journal of Nuclear Medicine, 2000, v. 41, n. 12, p. 1999
- By:
- Publication type:
- Article
Monoclonal Antibodies Labeled with Rhenium-186 Using the MAG3 Chelate: Relationship between the Number of Chelated Groups and Biodistribution Characteristics.
- Published in:
- Journal of Nuclear Medicine, 1996, v. 37, n. 2, p. 352
- By:
- Publication type:
- Article
<sup>89</sup>Zr-Labeled High-Density Lipoprotein Nanoparticle PET Imaging Reveals Tumor Uptake in Patients with Esophageal Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1880, doi. 10.2967/jnumed.121.263330
- By:
- Publication type:
- Article
<sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263330
- By:
- Publication type:
- Article
<sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263330
- By:
- Publication type:
- Article
<sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263330
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262473
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
The navigating and de-risking role of <sup>89</sup>Zr-immuno-PET in the development of biopharmaceuticals.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.239558
- By:
- Publication type:
- Article
<sup>89</sup>Zr-immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.224568
- By:
- Publication type:
- Article
Brain Access of Monoclonal Antibodies as Imaged and Quantified by <sup>89</sup>Zr-Antibody PET: Perspectives for Treatment of Brain Diseases.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.220939
- By:
- Publication type:
- Article
Fully Automated <sup>89</sup>Zr Labeling and Purification of Antibodies.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 5, p. 691, doi. 10.2967/jnumed.118.217158
- By:
- Publication type:
- Article
Brain Access of Monoclonal Antibodies as Imaged and Quantified by <sup>89</sup>Zr-Antibody PET: Perspectives for Treatment of Brain Diseases.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 5, p. 615, doi. 10.2967/jnumed.118.220939
- By:
- Publication type:
- Article
In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody--Drug Conjugates: Taking Advantage of Dual Labeling with <sup>195m</sup>Pt and <sup>89</sup>Zr.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 7, p. 1146, doi. 10.2967/jnumed.117.206672
- By:
- Publication type:
- Article